Takeshi Ueyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takeshi Ueyama has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Masunori Matsuzaki
Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
10 shared publications - Akihiko Shimizu
Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine
7 shared publications Akira Sawa
Division of Cardiology , Yamaguchi University Graduate School of Medicine , 1-1-1 Minami-Kogushi, Ube 755-8505 , Japan
4 shared publicationsJutaro Yamada
Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
4 shared publications- Shigeki Kobayashi
Yamaguchi University School of Medicine
4 shared publications - Akihiko Shimizu
Department of Cardiology, Ube-Kohsan Central Hospital, Ube 755-0151, Japan
3 shared publications
Latest Publications
- Open Access
- 21 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (6) , 1732
The Differential Prognostic Impact of Long-Duration Atrial High-Rate Episodes Detected by Cardiac Implantable Electronic Devices between Patients with and without a History of Atrial Fibrillation
Long-duration atrial high-rate episodes (AHREs) monitored using cardiac implantable electronic devices (CIEDs) can predict long-term major adverse cardiovascular events (MACEs). This study aimed to compare the impact of long-duration AHRE on MACE development between patients with and without a history of atrial fibrillation (AF). This single-center observational study included 132 CIED-implanted patients with AHREs detected via remote monitoring. The population was dichotomized into groups: with (n = 69) and without (n = 63) AF. In each group, cumulative incidences of MACEs comprising all-cause deaths, heart failure hospitalizations, strokes, and acute coronary syndromes were compared between patients with AHRE durations of ≥24 h and p = 0.005). MACE incidence did not significantly differ between AHRE ≥24 h and p = 0.44). After a multivariate adjustment, AHRE duration of ≥24 h emerged as the only independent predictor of MACEs among patients without AF (p = 0.03). In conclusion, a long-duration AHRE was prognostic in patients without a history of AF but not in patients with a history of AHREs.
- 21 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (6) , 1732
Open AccessThe Differential Prognostic Impact of Long-Duration Atrial High-Rate Episodes Detected by Cardiac Implantable Electronic Devices between Patients with and without a History of Atrial Fibrillation
Long-duration atrial high-rate episodes (AHREs) monitored using cardiac implantable electronic devices (CIEDs) can predict long-term major adverse cardiovascular events (MACEs). This study aimed to compare the impact of long-duration AHRE on MACE development between patients with and without a history of atrial fibrillation (AF). This single-center observational study included 132 CIED-implanted patients with AHREs detected via remote monitoring. The population was dichotomized into groups: with (n = 69) and without (n = 63) AF. In each group, cumulative incidences of MACEs comprising all-cause deaths, heart failure hospitalizations, strokes, and acute coronary syndromes were compared between patients with AHRE durations of ≥24 h and p = 0.005). MACE incidence did not significantly differ between AHRE ≥24 h and p = 0.44). After a multivariate adjustment, AHRE duration of ≥24 h emerged as the only independent predictor of MACEs among patients without AF (p = 0.03). In conclusion, a long-duration AHRE was prognostic in patients without a history of AF but not in patients with a history of AHREs.
- 14 August 2015
- Published by Elsevier in Heart Rhythm
- Vol. 13 (1) , 289-298
Cardiac sodium channel mutation associated with epinephrine-induced QT prolongation and sinus node dysfunction
- 14 August 2015
- Published by Elsevier in Heart Rhythm
- Vol. 13 (1) , 289-298
Cardiac sodium channel mutation associated with epinephrine-induced QT prolongation and sinus node dysfunction
- 30 September 2011
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 17 (9) , S172-S173
New Diagnostic Test for Arrhythmogenic Right Ventricular Cardiomyopathy
- 30 September 2011
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 17 (9) , S172-S173
New Diagnostic Test for Arrhythmogenic Right Ventricular Cardiomyopathy
- 1 January 2011
- Published by Wiley in Journal of Arrhythmia
- Vol. 27 (Supplement) , OP21_3
The Safety of Amiodarone for Heart Failure Patients with Atrial Fibrillation
- 1 January 2011
- Published by Wiley in Journal of Arrhythmia
- Vol. 27 (Supplement) , OP21_3
The Safety of Amiodarone for Heart Failure Patients with Atrial Fibrillation
- 30 September 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (9) , S152
Risk Stratification of Chronic Heart Failure by the Combination of Urinary 8-Hydroxy-2'-Deoxyguanosine and Plasma Brain Natriuretic Peptide
- 30 September 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (9) , S152
Risk Stratification of Chronic Heart Failure by the Combination of Urinary 8-Hydroxy-2'-Deoxyguanosine and Plasma Brain Natriuretic Peptide
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 665a
Drug-induced Brugada ECG Changes Associated With A Novel SCN5A Mutation In A Patient With Atrial Arrhythmias
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 665a
Drug-induced Brugada ECG Changes Associated With A Novel SCN5A Mutation In A Patient With Atrial Arrhythmias
- Open Access
- 24 November 2007
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 10 (1) , 86-90
Pilsicainide-induced Brugada-type ECG and ventricular arrhythmias originating from the left posterior fascicle in a case with Brugada syndrome associated with idiopathic left ventricular tachycardia
The patient was a 50-year-old male in 2002, who was first suspected of having a Brugada-type electrocardiogram (ECG). A drug challenge test using pilsicainide was performed and unmasked a typical coved type ST elevation followed by ventricular arrhythmias (VAs) manifesting a QRS pattern with a right bundle branch block and left axis deviation. Three years later, he was transferred to the emergency room due to a wide QRS tachycardia with the same QRS morphology as the VA that previously occurred in the drug challenge test. An ECG just after the recorded termination of the tachycardia exhibited a typical Brugada-type ECG. In an electrophysiological study, ventricular fibrillation could be easily induced with reproducibility. Since the clinical tachycardia could not be sustained by an isoproterenol infusion, mapping and catheter ablation targeting the pilsicainide-induced VAs was performed. The successful ablation site was the left mid-lower septal wall where a Purkinje potential was recorded and a false tendon was attached just to it.
- 24 November 2007
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 10 (1) , 86-90
Open AccessPilsicainide-induced Brugada-type ECG and ventricular arrhythmias originating from the left posterior fascicle in a case with Brugada syndrome associated with idiopathic left ventricular tachycardia
The patient was a 50-year-old male in 2002, who was first suspected of having a Brugada-type electrocardiogram (ECG). A drug challenge test using pilsicainide was performed and unmasked a typical coved type ST elevation followed by ventricular arrhythmias (VAs) manifesting a QRS pattern with a right bundle branch block and left axis deviation. Three years later, he was transferred to the emergency room due to a wide QRS tachycardia with the same QRS morphology as the VA that previously occurred in the drug challenge test. An ECG just after the recorded termination of the tachycardia exhibited a typical Brugada-type ECG. In an electrophysiological study, ventricular fibrillation could be easily induced with reproducibility. Since the clinical tachycardia could not be sustained by an isoproterenol infusion, mapping and catheter ablation targeting the pilsicainide-induced VAs was performed. The successful ablation site was the left mid-lower septal wall where a Purkinje potential was recorded and a false tendon was attached just to it.
- 1 January 2007
- Published by The Japanese Society of Electrocardiology in Japanese Journal of Electrocardiology
- Vol. 27 (Suppl4) , 22-26
Clinical characteristics in patients with Brugada type ECG associated with only supuraventricular arrhythmias
- 1 January 2007
- Published by The Japanese Society of Electrocardiology in Japanese Journal of Electrocardiology
- Vol. 27 (Suppl4) , 22-26
Clinical characteristics in patients with Brugada type ECG associated with only supuraventricular arrhythmias
- 1 January 2006
- Published by The Japanese Society of Electrocardiology in Japanese Journal of Electrocardiology
- Vol. 26 (Suppl4) , 102-106
Pilsicainide challenge test and inducibility of ventricular fibrillation by programmed electrical stimulation
- 1 January 2006
- Published by The Japanese Society of Electrocardiology in Japanese Journal of Electrocardiology
- Vol. 26 (Suppl4) , 102-106
Pilsicainide challenge test and inducibility of ventricular fibrillation by programmed electrical stimulation